Contrast-enhanced breast mri for cancer detection using a commercially available system—a perspective

1998 ◽  
Vol 22 (3) ◽  
pp. 162-179 ◽  
Author(s):  
Julian Safir ◽  
Joseph L Zito ◽  
Mark E Gershwind ◽  
David Faegenburg ◽  
Corinne E Tobin ◽  
...  
2006 ◽  
Vol 24 (10) ◽  
pp. 1363-1367 ◽  
Author(s):  
Julia Po ◽  
Daniel J.A. Margolis ◽  
Charles H. Cunningham ◽  
Robert J. Herfkens ◽  
Debra M. Ikeda ◽  
...  

2021 ◽  
Vol 11 ◽  
pp. 63
Author(s):  
Gesine Peters ◽  
Anne Margaret Lynch ◽  
Johannes Peters

Contrast-enhanced mammography (CEM) is a new technology in breast imaging and cancer detection. It has been shown to have a comparable performance to breast MRI. Currently, there is no independent BI-RADS lexicon available for CEM. This pictorial essay will demonstrate the use of breast MRI descriptors according to the BI-RADS breast MRI lexicon, to describe enhancement patterns for recombined CEM images. The authors recommend using enhancement pattern descriptors already in use for breast MRI when reporting CEM studies, to promote uniformity of interpretation and reporting.


2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 11069-11069 ◽  
Author(s):  
Lydia Liao ◽  
Luna Li ◽  
Pauline Germaine ◽  
Elizabeth Tinney

2019 ◽  
Vol 1 (1) ◽  
pp. 64-72 ◽  
Author(s):  
Jordana Phillips ◽  
Valerie J Fein-Zachary ◽  
Priscilla J Slanetz

Abstract Contrast-enhanced mammography (CEM) is a promising new imaging modality that uses a dual-energy acquisition to provide both morphologic and vascular assessment of breast lesions. Although no official BI-RADS lexicon exists, interpretation entails using the mammographic BI-RADS lexicon in combination with that for breast MRI. CEM has comparable performance to breast MRI, with sensitivity of 93–100% and specificity of 80–94%. Currently FDA approved for diagnostic imaging, this technology can be helpful in determining disease extent in patients with newly diagnosed breast malignancy, monitoring response to neoadjuvant therapy, identifying mammographically occult malignancies, and diagnostic problem-solving. Studies are ongoing about its role in screening, especially in women with dense breasts or at elevated risk. There are some challenges to successful implementation into practice, but overall, patients tolerate the study well, and exam times are less than the full breast MRI protocol.


2017 ◽  
Vol 20 (2) ◽  
pp. 97-109 ◽  
Author(s):  
Vasileios Rafailidis ◽  
Afroditi Charitanti ◽  
Thomas Tegos ◽  
Evangelos Destanis ◽  
Ioannis Chryssogonidis

Author(s):  
Dian Yuan Lu ◽  
Lan Liu ◽  
Li Shen ◽  
Jian Rong Cai ◽  
Li Xu ◽  
...  

OBJECTIVE: To investigate prostate cancer detection rate of different biopsy protocols in different PSA value groups in rural China. METHODS: A total of 186 patients underwent contrast-enhanced ultrasound (CEUS) in order to determine the puncture target prior to biopsy were enrolled in this retrospective study. All patients underwent 12-core SB combined with CEUS-TB. The biopsy results of different biopsy protocols were compared in patients with stratification by PSA value. RESULTS: Among the 186 patients underwent prostate biopsy, the histopathologic results revealed prostate cancer (PCa) in 117 cases (62.9%) and benign lesions in 69 cases (37.1%). The PCa detection rate between 8-core SB and 12-core SB showed no significant difference in PSA 4–10 ng/ml group, while the 12-core SB was significantly higher than CEUS-TB (44.9% versus 32.7% , P = 0.01). In PSA 10–20 ng/ml group, the significant difference was not seen between SB and CEUS-TB (50.0% versus 45.7% , P = 0.15). As for PSA greater than 20 ng/ml group, the PCa detection rate by SB was higher than CEUS-TB, but showed no statistically significance (79.1% versus 76.9% , P = 0.15). In the overall patients, the biopsy core positive rate of CEUS-TB was significantly higher than SB (97% versus 55.5% and 28.5% , P = 0.0001). CONCLUSION: The flexible use of SB combined with CEUS-TB can reduce the number of biopsy cores in higher PSA groups. It has clinical importance in the detection of PCa in different PSA value groups in rural China.


Author(s):  
Kendrah V Osei ◽  
Anita K Mehta ◽  
Denise M Thigpen ◽  
Jocelyn Rapelyea ◽  
Steven Friedman ◽  
...  

Abstract Objective To compare cancer detection rate (CDR), patient recall, and interpretation time of a full protocol MRI (fpMRI) to an abbreviated MRI protocol (abMRI) in high-risk women. Methods This retrospective study was approved by the IRB. All sequential high-risk screening MRI examinations performed between January 1, 2013, and December 31, 2016, were included. Breast radiologists reviewed patient history, prior images, and abMRI images and recorded their interpretation. Time for interpretation reflected review of the MRI study but not dictation or report generation. Following a minimum 30-day washout period, radiologists interpreted the fpMRI, with interpretation and timing recorded. Data collected included CDR, interpretation time, and patient recall rate. Statistical analyses utilized were Cohen’s kappa coefficient, Student’s t-test, and McNemar’s test. Results Included were 334 MRI examinations of 286 women. Interpretation time was 60.7 seconds for the abMRI compared to 99.4 seconds for the fpMRI, with an average difference of 38.7 ± 5.4 seconds per patient (P < 0.0001). Recall rates were comparable: the abMRI recall rate was 82/334 (24.6%) and the fpMRI 81/334 (24.3%). All five cancers included were detected by both protocols with equal recall rate. However, there were more recommendations for biopsy with the fpMRI, although this difference was not statistically significant. Conclusion The abMRI demonstrated comparable CDR to fpMRI, with shortened interpretation time and similar recall rates. Implementing an abMRI to screen high-risk women reduces imaging and interpretation time, thereby improving cost-effectiveness and the patient experience without reduction in cancer detection.


Sign in / Sign up

Export Citation Format

Share Document